Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Holding PDSB?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.35Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 01, 2019
|% Change Since: -44.93%
|Next Earnings Date:May 14, 2019
Earnings Call Sentiment|Positive
The earnings call highlighted strong progress in clinical trials with significant improvements in clinical outcomes and promising data from IMMUNOCERV Phase II. Despite increased R&D expenses and some delays in other development areas, the overall sentiment is positive due to robust clinical results and strong interest in ongoing trials.Company Guidance
During the third quarter earnings call for PDS Biotech on November 14, 2024, the company provided guidance on several key metrics and strategic updates. The VERSATILE-003 Phase III trial design was revised to include approximately 350 patients, maintaining its statistical power with a 2:1 randomization, and aligning with FDA registrational trial design discussions. Median overall survival remains the primary endpoint, with FDA clearance expected by mid-December 2024. The decision to adjust the trial design was informed by data from the VERSATILE-002 study, where median overall survival remained at 30 months, and objective response rate improved to 36%. The company reported a net loss of approximately $10.7 million for the quarter, with cash and cash equivalents totaling $50 million as of September 30, 2024. Additionally, PDS Biotech plans to initiate the VERSATILE-003 trial in the first quarter of 2025, leveraging existing resources and investor interest.Strong Interest in VERSATILE-003 Trial
Both investor and investigator interest in the VERSATILE-003 trial is strong, with minor modifications made to reduce cost and time for interim data readout and completion.
Clinical Success in VERSATILE-002
Improved median overall survival of 30 months, objective response rate from 26% to 36%, and disease control rate from 70% to 77% in the VERSATILE-002 study.
IMMUNOCERV Phase II Encouraging Results
Promising clinical activity and safety profile in the IMMUNOCERV Phase II trial, with a 100% 36-month overall survival rate for patients who received all 5 doses of Versamune HPV.
Improved Financial Position
Cash and cash equivalents totaled approximately $50 million as of September 30, 2024.
---
PDSB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PDSB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $2.76 | $2.25 | -18.48% |
| Aug 13, 2024 | $3.05 | $3.05 | 0.00% |
| May 15, 2024 | $3.54 | $3.50 | -1.13% |
| Mar 27, 2024 | $4.48 | $3.85 | -14.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PDS Biotechnology Corporation (PDSB) report earnings?
PDS Biotechnology Corporation (PDSB) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is PDS Biotechnology Corporation (PDSB) earnings time?
PDS Biotechnology Corporation (PDSB) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PDSB EPS forecast?
PDSB EPS forecast for the fiscal quarter 2024 (Q4) is -0.31.
---